Metformin and Vildagliptin 850

PreclinicalSmall molecule

AAET Laboratories Private Limited

Metformin and Vildagliptin 850 is one of 82 small molecule programs targeting TED. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TEDCompleted

ESSCompleted

TEDPreclinical

Completed

ESSPreclinical

Completed

Competition

Competitive Landscape

56 competitors in ESS

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

7 2

Proamatine

Takeda

Approved

2 3

Quviviq

Idorsia Pharmaceuticals Ltd.

Approved

1 4

Opdualag

Bristol-Myers Squibb

Phase 2

2 5

Opdivo

Bristol-Myers Squibb

Phase 2

2 6

Darzalex

Johnson & Johnson

Phase 2

1 7

Decadron

AAspen Global Incorporated

Phase 2

1 8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 9

Kyprolis

VVirionyx Corporation Limited

Phase 2

1 10

Mineral Trioxide Aggregate

JJordan University of Science and Technology

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

TED1 trial

The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.

Completed·AAET Laboratories Private Limited·N/A·NCT05329857·60 enrolled

ESS1 trial

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.

Completed·AAET Laboratories Private Limited·N/A·NCT05337969·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Metformin and Vildagliptin 850. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metformin and Vildagliptin 850 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metformin and Vildagliptin 850. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AET Laboratories Private Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAET Laboratories Private Limited

Metformin and Vildagliptin 850

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

TED1 trial

ESS1 trial

References

Drug Info

Quick Facts

Related News